A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics

PURPOSE: Quizartinib, a potent, selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, is currently in phase 3 development for patients with FLT3–internal tandem duplication-mutated acute myeloid leukemia (AML). Acid-reducing agents (ARAs; e.g., proton pump inhibitors) are frequently used during AML...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianke, Trone, Denise, Mendell, Jeanne, O’Donnell, Patrick, Cook, Natalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768889/
https://www.ncbi.nlm.nih.gov/pubmed/31385001
http://dx.doi.org/10.1007/s00280-019-03915-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768889/
https://www.ncbi.nlm.nih.gov/pubmed/31385001
http://dx.doi.org/10.1007/s00280-019-03915-1

Ejemplares similares